Alnylam Pharma (ALNY) Tops Q3 EPS by 15c, Misses on Revenue, Offers FY22 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity
October 27, 2022 8:00 AM EDTAchieved Third Quarter 2022 Global Net Product Revenues of $232 Million for ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®
Strong First Full Quarter of AMVUTTRA in U.S.: Achieving $25 Million in Net Product Revenues and Driving 30% U.S. Total TTR Growth Compared with Q2 2022
Reported Positive Results from the APOLLO-B Phase 3 Study of Patisiran, and Remains on Track for a Supplemental New Drug Application (sNDA) Submission in Late 2022
Reiterated 2022 Combined Net Product Revenue Guidance of $870-$930 Million
CAMBRIDGE, Mass.--(BUSINESS... More
